undamentalytics Newsletter
Sign in

Nanobiotix S.a. revenue

Nanobiotix S.a.'s revenue was $36.9m in fiscal 2025. Since fiscal 2018 ($4.1m) it has grown at a compound 36.8% a year.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025
Revenue4333539−837
Growth on the year before—−30.8%+0.8%+9.3%+60.7%+678.4%−119.9%—

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Nanobiotix S.a. $36.9m 678.4% —
Foghorn Therapeutics Inc. $36.7m 52.0% 19.1%
Zymeworks Inc. $37.1m -69.8% -56.4%
Cue Biopharma, Inc. $37.7m 354.4% 176.2%
C4 Therapeutics, Inc. $35.0m 2.3% 29.8%
Bioharvest Sciences Inc. $34.5m 37.0% —

Compare with peers

Head to head: FHTX vs NBTXNBTX vs ZYMECUE vs NBTX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Nanobiotix S.a.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Nanobiotix S.a.